Unlock instant, AI-driven research and patent intelligence for your innovation.

A crystal form of lolatrexex hydrochloride and its preparation method and application

A technology of loratrex hydrochloride and crystal form, which is applied in the field of new crystal forms of compounds, can solve problems such as loratrex hydrochloride that have not yet been seen, achieves stable and mass production, is beneficial to popularization and application, and has good yield Effect

Inactive Publication Date: 2016-08-10
BEIJING KONRUNS PHARM CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the published literature reports, there is no report on the polymorphic form of lolatrexex hydrochloride

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A crystal form of lolatrexex hydrochloride and its preparation method and application
  • A crystal form of lolatrexex hydrochloride and its preparation method and application
  • A crystal form of lolatrexex hydrochloride and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Preparation of crude Lolatrox hydrochloride

[0042] Add 5 g of loratrox to a mixed solution of 10 ml of water and 33 ml of methanol, add 1.0 ml of concentrated hydrochloric acid, and heat to completely dissolve. Tetrahydrofuran was added dropwise to precipitate crystals, and the crude Lolatrox hydrochloride was obtained by filtration after standing for crystallization according to conventional methods. The powder X-ray diffraction pattern is shown in figure 2 .

Embodiment 2

[0043] Example 2 Lolatrox hydrochloride crystal form I and its preparation

[0044] Add 5 g of the crude Lolatrox hydrochloride (prepared in Example 1) into 10 ml of purified water, add 0.25 ml of concentrated hydrochloric acid, and raise the temperature to 60° C. to completely dissolve. The temperature was lowered to 45°C and acetone was added dropwise to precipitate crystals, and the crystals were incubated for 60 minutes. Continue to add acetone dropwise to make the total amount of acetone added twice to 50ml. Cultivate the crystals at 45°C for 60 minutes. Slowly reduce to 20-25℃ under stirring, and cultivate the crystal for 120 minutes. Filter and wash 3 times with 15 ml of 85% acetone aqueous solution. The filter cake was vacuum dried at 35°C to constant weight. Lolatrox hydrochloride crystal form I was obtained with a purity of 99.7% and a yield of 92.6%.

[0045] Such as figure 1 As shown, the crystalline form I of loratrax hydrochloride was determined by powder X-ray d...

Embodiment 3

[0046] Example 3 Lolatrox hydrochloride crystal form I and its preparation

[0047] Add 5 g of the crude Lolatrox hydrochloride (prepared in Example 1 or commercially available raw material) to 7.5 ml of purified water, add 0.1 ml of concentrated hydrochloric acid, and raise the temperature to 50° C. for complete dissolution. The temperature was lowered to 40°C and acetone was added dropwise to precipitate crystals, and the crystals were incubated for 45 minutes. Continue to add acetone dropwise to bring the total amount of acetone added twice to 40ml. Cultivate the crystals at 45°C for 45 minutes. Slowly reduce to 20°C while stirring, and cultivate crystals for 90 minutes. Filter and wash 3 times with 15 ml of 85% acetone aqueous solution. The filter cake was vacuum-dried at 35°C to constant weight to obtain the crystal form I of lolatrox hydrochloride with a purity of 99.6 and a yield of 91%.

[0048] Such as figure 1 As shown, the crystalline form I of loratrax hydrochloride...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses a crystal form I of nolatrexed hydrochloride. The crystal form I of nolatrexed hydrochloride is determined by using X-ray powder diffractometry. In an X-ray powder diffraction pattern represented by the diffraction angle 2theta + / - 0.2 DEG, characteristic diffraction peaks appear at 8.993 DEG, 9.205 DEG, 9.342 DEG, 14.296 DEG, 14.601 DEG, 17.836 DEG, 18.534 DEG, 22.041 DEG, 22.334 DEG, 22.682 DEG, 26.792 DEG, 27.160 DEG, 27.396 DEG, 27.845 DEG, 29.652 DEG and 30.819 DEG. The crystal form provided by the invention has not been reported, has a clear outline, can be perfectly reproduced, shows valuable features in the aspects of filtering, drying, stability, methods of preparation and processability, is applicable as an antitumor drug and has broad application prospects.

Description

Technical field [0001] The present invention relates to a new crystal form of a compound, in particular to a loratrax hydrochloride and a preparation method and application thereof. Background technique [0002] Lolatrox hydrochloride was first developed abroad by Agouron Pharmaceuticals. The company synthesized a series of thymidylate synthase inhibitors based on the three-dimensional structure characteristics of the enzyme active center and used computer-simulated drug molecular technology to synthesize a series of thymidylate synthase inhibitors. Lolatrox hydrochloride is one of the compounds that inhibit the activity of thymidylate synthase. The company cooperated with Roche Switzerland to develop loratraxine hydrochloride as an anti-tumor drug under the trade name "Thymitaq". The drug began clinical trials in 1994 and entered phase III clinical trials in August 1996. In January 1999, Agouron Pharmaceuticals adjusted its product strategy and exclusively transferred all the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/12A61K31/517A61K9/19A61P35/00
CPCC07D401/12
Inventor 王锡娟
Owner BEIJING KONRUNS PHARM CO LTD